trending Market Intelligence /marketintelligence/en/news-insights/trending/lky97ysk5sucffc3xzve9a2 content esgSubNav
In This List

PolarityTE names 2 new board members


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

PolarityTE names 2 new board members

Salt Lake City-based biotechnology company PolarityTE Inc. said it added two new directors to its board.

The developer of regenerative medicines appointed Ramses Erdtmann to the board, replacing Ned Swanson who will continue to work as the company's COO. Concurrently, the company said David Seaburg will be joining its board.

Erdtmann works as a managing partner at Point Sur Investors, a biotech investment fund. He previously worked at Pharmacyclics from 2008 through 2015, helping the company grow from 47 employees and a market cap of $20 million to 634 employees and a market cap of $21 billion, PolarityTE said in a statement.

Pharmacyclics was acquired by pharmaceutical giant AbbVie Inc. in 2016.

Seaburg is currently the managing director and head of sales trading at Cowen Inc., a financial services firm.

"Ramses' operational experience at Pharmacyclics during its transition into a multi-billion dollar commercial biotech company and David's investment expertise, long tenure at Cowen, and experience with healthcare management teams will be tremendously valuable as PolarityTE continues to execute on the business," PolarityTE CEO Denver Lough said in a statement.

PolarityTE markets SkinTE which is used to repair, reconstruct, replace or supplement a patient's damaged or missing skin tissue.